Are All Alpha-Blockers Created the Same?
Wednesday, 01 March 2006
In the next decade, the number of men who will consult for lower urinary tract symptoms (LUTS), often in connection with benign prostatic hyperplasia (BPH), will increase for two reasons: the population is aging and fewer and fewer men will consider LUTS as an inevitable mark of old age and accept this bothersome condition without seeking treatment. We should also expect continuity in the current management trend diminishing surgical intervention; medical therapy will take a more prominent role.
read more
|
European Urology - Lasers for the Treatment of Bladder Outlet Obstruction: Are They Challenging Conventional Treatment Modalities?
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 418-420 (September 2006) Benign prostatic hyperplasia (BPH) is the most common benign neoplasm among aging men and, at the same time, the most frequent male tumor requiring surgical intervention. Transurethral resection of the prostate (TURP) still remains the “reference” instrumental treatment for benign prostatic obstruction, but the significant morbidity related to this surgical procedure has powered the development of various high-energy alternative treatment options.
read more
|
European Urology - A Randomised Trial Comparing Holmium Laser Enucleation Versus Transurethral Resection in the Treatment of Prostates Larger Than 40Grams: Results at 2 Year
Tuesday, 05 September 2006
Volume 50, Issue 3, Pages 569-573 (September 2006) 1. Introduction The surgical management of men with large prostates (>40g) that cause bladder outflow obstruction (BOO) secondary to benign prostatic hyperplasia (BPH) is a challenging area.
read more
|
European Urology - Unexpected Insights into Pelvic Function Following Phosphodiesterase Manipulation—What's Next for Urology?
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1153-1156 (December 2006) Article Outline: The review article concerning phosphodiesterases (PDEs) submitted by Ückert et al. is both excellent and comprehensive in its evaluation of the PDE isoenzymes and their potential role in various urologic settings [1].
read more
|
European Urology - Systemic Nitric Oxide Augmentation Leads to a Rapid Decrease of the Bladder Outlet Resistance in Healthy Men
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 112-118 (July 2006) Abstract -
Objective:
We examined the immediate effect of a systemic nitric oxide augmentation on the bladder outlet resistance in healthy men.
read more
|
European Urology - Medical Management of BPH: The Debate Continues
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 416-417 (September 2006) After more than 15 years of extensive clinical research in the medical management of BPH one would expect that it has now become clear how to treat.
read more
|
Comparison of the Cardiovascular Effects of Tamsulosin Oral Controlled Absorption System (OCAS®) and Alfuzosin Prolonged Release (XL)
Monday, 06 March 2006
Objective: The cardiovascular (CV) effects of tamsulosin oral controlled absorption system (OCAS®) 0.4mg were compared with those of alfuzosin prolonged release (XL) 10mg.
read more
|
European Urology - Correlations between Longitudinal Changes in Transitional Zone Volume and Measures of Benign Prostatic Hyperplasia in a Population-Based Cohort
Wednesday, 28 June 2006
Volume 50, Issue 1, Pages 105-111 (July 2006) Abstract -
Objective:
To determine whether measures of transitional zone volume (TZV) are more strongly associated than total prostate volume with longitudinal urologic outcomes.
read more
|
European Urology - Micronutrients and BPH
Tuesday, 29 August 2006
Volume 50, Issue 3, Pages 413-415 (September 2006) Descriptive epidemiology suggests that the incidence and prevalence of prostatic diseases vary significantly in different areas of the world [1], [2], [3]. Possible reasons for such wide variations have been explored and nutritional factors were found to play a role together with genetic, behavioral, occupational, and environmental ones.
read more
|
European Urology - Holmium Laser Enucleation of the Prostate Versus Open Prostatectomy for Prostates >70g: 24-Month Follow-up
Thursday, 31 August 2006
Volume 50, Issue 3, Pages 563-568 (September 2006) 1. Introduction: Open prostatectomy (OP) is the most common surgical approach for benign prostate hyperplasia (BPH) in large prostates in many parts of Europe [1], [2].
read more
|
European Urology - Characteristics of Patients Presenting with LUTS/BPH in Six European Countries
Friday, 01 September 2006
Volume 50, Issue 3, Pages 555-562 (September 2006) Abstract - Objectives: Knowledge of the clinical profile of the population with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH) is important for health care management, impacting on manpower requirements, pharmacologic demands and health service costs.
read more
|
European Urology - Anticholinergic Drugs in Patients with Bladder Outlet Obstruction and Lower Urinary Tract Symptoms: Where do we Stand in 2006?
Wednesday, 20 September 2006
Volume 50, Issue 4, Pages 653-654 (October 2006) The presence of storage symptoms is extremely common in patients with bladder outlet obstruction (BOO).
read more
|
European Urology - Intake of Selected Micronutrients and the Risk of Surgically Treated Benign Prostatic Hyperplasia: A Case-Control Study from Italy
Friday, 01 September 2006
Volume 50, Issue 3, Pages 549-554 (September 2006) 1. Introduction: Although benign prostatic hyperplasia (BPH) is a very common disease in older men [1], [2], little is known about its etiology [3], [4], except for an involvement of androgens in its development and maintenance [5], [6], [7].
read more
|
European Urology - Alfuzosin (10mg) Does Not Affect Blood Pressure in Young Healthy Men
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1292-1298 (December 2006) Abstract - Objectives: Alfuzosin 10mg is a uroselective α1-adrenoceptor antagonist used to treat lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Recent studies have suggested the potential efficacy of alfuzosin in the treatment of distal ureteral stones and prostatitis syndrome, two conditions frequently encountered in young patients.
read more
|
Holmium Laser Enucleation of the Prostate (HoLEP): The Endourologic Alternative to Open Prostatectomy
Monday, 02 January 2006
Objective: To evaluate HoLEP for patients with enlarged prostate (traditionally treated by open prostatectomy) with long-term follow-up.
read more
|
European Urology - BPH Treatment: A Paradigm Shift
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 939-941 (June 2006)
It took about a century to change the surgical treatment of benign prostatic hyperplasia (BPH) from open prostatectomy to transurethral resection.
read more
|
Medical Consumption and Costs during a One-Year Follow-up of Patients with LUTS Suggestive of BPH in Six European Countries: Report of the TRIUMPH Study
Monday, 02 January 2006
Objective: To determine the medical consumption and associated treatment costs of patients with LUTS suggestive of BPH.
read more
|
European Urology - Alpha antagonists—from initial concept to routine clinical practice
Sunday, 24 September 2006
Volume 50, Issue 4, Pages 635-642 (October 2006) It is a great honour and a pleasure for me to participate in this celebration of the 50th volume of European Urology by commenting on this landmark review paper by Marco Caine, who was the pioneer of pharmacotherapy for lower urinary tract symptoms (LUTS) suggestive of benign prostatic outlet obstruction (BOO; previously referred to as symptomatic benign prostatic hyperplasia [BPH]), which are so common in ageing men.
read more
|
A Shifted Paradigm for the Further Understanding, Evaluation, and Treatment of Lower Urinary Tract Symptoms in Men: Focus on the Bladder
Monday, 03 April 2006
Lower urinary tract symptoms (LUTS) are highly prevalent among older men and have a negative impact on health-related quality of life. Frequent comorbidity with potential prostatic disease adds complexity to the management of male LUTS.
read more
|
European Urology - Photoselective Vaporization of the Prostate: Subgroup Analysis of Men with Refractory Urinary Retention
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 1040-1049 (November 2006) Abstract - Objectives: The purpose of this study was to evaluate the feasibility and efficacy of photoselective vaporization of the prostate (PVP) in patients with refractory urinary retention (RUR) secondary to benign prostate hyperplasia (BPH).
read more
|
BXL628, A Novel Vitamin D3 Analog Arrests Prostate Growth in Patients with Benign Prostatic Hyperplasia: A Randomized Clinical Trial
Monday, 02 January 2006
Objective: To evaluate the effect of BXL628, a vitamin D3 analog, on prostate volume in patients with benign prostatic hyperplasia (BPH).
read more
|
European Urology - Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future
Thursday, 23 November 2006
Volume 50, Issue 6, Pages 1194-1207 (December 2006) 1. IntroductionThe cyclic nucleotide monophosphates (cNMPs) cAMP and cGMP are important intracellular regulators of several processes, including smooth muscle motility, electrolyte homeostasis, neuroendocrine signals and retinal phototransduction [1], [2].
read more
|
European Urology - Techniques and Long-Term Results of Surgical Procedures for BPH
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 970-978 (June 2006)
1. BackgroundThe urologist's armamentarium for treating lower urinary tract symptoms (LUTS) that are suggestive of bladder outlet obstruction (BOO) has been expanded dramatically within the last decade.
read more
|
European Urology - Complications of Transurethral Resection of the Prostate (TURP)—Incidence, Management, and Prevention
Wednesday, 25 October 2006
Volume 50, Issue 5, Pages 969-980 (November 2006) Abstract - Objectives: To update the complications of transurethral resection of the prostate (TURP), including management and prevention based on technological evolution.
read more
|
European Urology - Current Role of Lasers in the Treatment of Benign Prostatic Hyperplasia (BPH)
Thursday, 01 June 2006
Volume 49, Issue 6, Pages 961-969 (June 2006) 1. IntroductionTransurethral electrocautery resection of the prostate (TURP) is limited to small and medium-sized prostates. The overall morbidity rate is 15–20% [1], with blood transfusion rates between 5% and 11% [2]. Various lasers have been introduced as alternatives to TURP, mainly the neodymium:yttrium aluminium garnet (Nd:YAG), the holmium (Ho):YAG, and the frequency-doubled Nd:YAG (potassium-titanyl-phosphate [KTP]) laser.
read more
|
